Evidence map›Paper›PMID 30043333›Full record

Trial reportInternational journal of hematology2018

Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.

Hidekazu Itamura, Masaru Ide, Akemi Sato, Naoko Sueoka-Aragane, Eisaburo Sueoka, Aya Nishida, Taro Masunari, Sadao Aoki, Jun Takizawa, Junji Suzumiya and 1 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. [BRAF gene mutations in ameloblastic fibromas].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Hidekazu ItamuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Masaru IdeDepartment of Internal Medicine, Oda Hospital, Kashima, Japan.
Akemi SatoDepartment of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Naoko Sueoka-AraganeDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Eisaburo SueokaDepartment of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Aya NishidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Taro MasunariDepartment of Hematology, Chugoku Central Hospital, Hiroshima, Japan.
Sadao AokiDepartment of Pathophysiology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Junji SuzumiyaDepartment of Oncology/Hematology, School of Medicine, Shimane University, Izumo, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan. shkimu@cc.saga-u.ac.jp.
Saga University · JPChugoku Central Hospital · JPNiigata University · JPNiigata University of Pharmacy and Applied Life Sciences · JPShimane University · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hairy cell leukemia (HCL) is a rare B-cell lymphoid malignancy that is difficult to distinguish from other morphological variants. The frequency of HCL has not been determined accurately in Japan. Recent studies revealed that the BRAF V600E mutation is the causal genetic event in HCL. We assessed the BRAF mutation in Japanese patients with HCL and related diseases using the quenching probe (QP) method, a single-nucleotide polymorphism detection system, and evaluated the incidence rate of HCL among Japanese patients with chronic lymphocytic leukemia, and related diseases. We identified 18 cases (33.3%) harboring the BRAF mutation among 54 patients diagnosed with, or suspected of having HCL. Of BRAF V600E-positive patients, 7 were only detected using the QP method, not by direct sequencing, whereas 11 were positive using both tests. In a larger cohort of Japanese patients diagnosed with chronic lymphoid leukemia or related diseases, the frequency of HCL was 4%. Patients with the BRAF V600E mutation had a significantly higher frequency of neutropenia, thrombocytopenia, and elevated soluble interleukin-2 receptor and common B-cell surface markers than patients without the mutation. Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.

Indexed as

Mutation, MissenseNucleic Acid ProbesPolymorphism, Single NucleotideAdultAgedAged, 80 and overAmino Acid SubstitutionAsian PeopleFemaleHumansJapanLeukemia, Hairy CellMaleMiddle AgedProto-Oncogene Proteins B-rafBRAF protein, humanNucleic Acid ProbesProto-Oncogene Proteins B-rafBRAF V600EHairy cell leukemiaJapanLow-grade B-cell malignancyQuenching probe

Identifiers

PMID30043333
OpenAlexW2884411248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.